IRF4 and plasma cell myeloma: Notably, IRF4 translocation to actively transcribed genomic areas in some multiple myeloma (MM) patients is associated with carcinogenicity and overexpression, yet it confers a survival benefit in MM without translocations or amplifications [56,89].